X
J&J ends 2018 on a high, but coming year looks shaky
https://pharmaphorum.com/news/jj-ends-2018-on-a-high-but-coming-year-looks-shaky/
Remicade
Stelara gains US approval for Crohn’s disease
New use for patients who fail anti-TNF drugs
No US Remicade biosimilar until at least October
Pfizer must wait until 180 day period ends, court fight ongoing.
Biosimilar switching not suitable for all patients
Antibodies against originator will also target biosimilar.
